NDA 204427 · Anacor Pharms INC
Kerydin
Tavaborole · Topical
NovelDiscontinuedLast checked: Nov 20, 2026Latest source record: Jul 30, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Jul 7, 2014
Approved uses
2
Original approval plus efficacy supplements
Registered trials
11
2 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 30, 2018 Supplement 6 · Efficacy · priority review LabelLetterPediatric Medical Review
- Jul 7, 2014 Original approval · Type 1 - New Molecular Entity NovelReviewSummary ReviewPediatric Written Request
1 products under this application
- KERYDIN · TAVABOROLE 5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, TOPICAL · Discontinued · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Tavaborole" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the ToenailPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01302119 · 604 participants · Start Feb 2011 · Primary completion Dec 31, 2012
Drug: AN2690 Topical Solution, 5%; Solution Vehicle · For: Onychomycosis of Toenails
Sites: Phoenix, Arizona; Novato, California; Oceanside, California · 32 sites in all
- Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the ToenailPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01270971 · 594 participants · Start Dec 1, 2010 · Primary completion Nov 30, 2012
Drug: AN2690 Topical Solution, 5%; Solution Vehicle · For: Onychomycosis of Toenails
Sites: Tucson, Arizona; Hot Springs, Arkansas; Burbank, California · 27 sites in all
- Study of Different Doses of a Novel Treatment for OnychomycosisPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00679965 · 159 participants · Start Feb 28, 2006 · Primary completion Jul 31, 2007
Drug: AN2690, 2.5%; AN2690, 5% and 2 more · For: Distal, Subungual Onychomycosis
Sites: Chihuahua City, Mexico; Guadalajara, Mexico; Mexico City, Mexico · 9 sites in all
PfizerPfizer (PFE)
NCT00679523 · 60 participants · Start Nov 2005 · Primary completion Feb 2007
Drug: AN2690 Solution, 5.0%; AN2690 Solution, 7.5% · For: Onychomycosis
Sites: Chihuahua City, Mexico; Guadalajara, Mexico; Mexico City, Mexico · 9 sites in all
- Safety and Efficacy Evaluation of Topically Applied AN2690 Solutions for Subjects With OnychomycosisCompleted
PfizerPfizer (PFE)
NCT00680134 · 60 participants · Start Jun 30, 2006 · Primary completion Aug 31, 2007
Drug: AN2690; AN2690 · For: Onychomycosis
Sites: Birmingham, Alabama; San Francisco, California; Albuquerque, New Mexico · 7 sites in all
PfizerPfizer (PFE)
NCT03405818 · 55 participants · Start Oct 22, 2015 · Primary completion Jul 27, 2017
Drug: Tavaborole 5% Topical Solution · For: Onychomycosis; Tinea Unguium
Sites: Madera, California; Palo Alto, California; Washington D.C., District of Columbia · 12 sites in all
- Cumulative Irritation TestCompleted
PfizerPfizer (PFE)
NCT00680095 · 37 participants · Start Jan 22, 2007 · Primary completion Feb 19, 2007
Drug: AN2690; AN2690 and 1 more · For: Onychomycosis
Sites: Lynchburg, Virginia
PfizerPfizer (PFE)
NCT01278394 · 29 participants · Start Mar 2007 · Primary completion Jul 2008
Drug: AN2690 Solution, 5.0% · For: Onychomycosis
Sites: Guadalajara, Mexico; Mexico City, Mexico
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Antifungal Drug Use for Onychomycosis.
Thomas J, Peterson GM, Christenson JK, et al. · Am J Ther 2019 · Systematic Review
- Tavaborole in Difficult-to-Treat Onychomycosis Cases: A Post-hoc Assessment of Phase III Subjects.
Aly R, Gupta AK, Winter T, et al. · J Drugs Dermatol 2017 · Case Reports, Clinical Trial, Phase III
- Topical and device-based treatments for fungal infections of the toenails.
Foley K, Gupta AK, Versteeg S, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Planimetric Post-hoc Analysis of Women With Onychomycosis from Tavaborole 5% Phase III Studies: Evidence of Greater Improvements in Patients With >50% Baseline Infection.
Pariser DM, Wendelken ME, Rycerz AM, et al. · J Drugs Dermatol 2018 · Clinical Trial, Phase III, Multicenter Study
- Tavaborole 5% Topical Solution for the Treatment of Toenail Onychomycosis in Pediatric Patients: Results from a Phase 4 Open-Label Study.
Rich P, Spellman M, Purohit V, et al. · J Drugs Dermatol 2019 · Clinical Trial, Phase IV
- Topical Tavaborole in the Treatment of Onychomycosis Complicated by Dermatophytoma: A Post-hoc Assessment of Phase II Subjects.
Aly R, Winter T, Hall S, et al. · J Drugs Dermatol 2018 · Clinical Trial, Phase II, Randomized Controlled Trial
Sponsor: Anacor Pharms INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.